Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostatic acid phosphatase (PAP), also known as prostatic specific acid phosphatase (PSAP), is an enzyme produced primarily by the epithelial cells of the prostate gland. It catalyzes the dephosphorylation of organic monophosphate esters with optimal activity at acidic pH. Elevated serum levels are primarily found in metastatic or advanced-stage prostate cancer, but can also be increased in other conditions. Recent research indicates a role in dephosphorylating ErbB-2/Neu/HER-2, impacting tumorigenicity and androgen sensitivity. Measurement of serum PAP aids prognosis assessment for prostate cancer patients.
Dephosphorylation of target proteins, including ErbB-2/Neu/HER-2
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostatic Acid Phosphatase (None).